GLP-1 RAs reduce major cardiovascular events by 14% through multiple mechanisms beyond glucose control, including anti-inflammatory effects and blood pressure reduction SELECT trial proved cardiovascular benefits extend to non-diabetic patients with obesity, showing 20% MACE reduction in those without diabetes Semaglutide, liraglutide, and dulaglutide demonstrate the strongest cardiovascular protection, with proven benefits in large outcome trials These agents provide specific benefits for heart failure with preserved ejection fraction and kidney protection, reducing albuminuria by 24% Current guidelines strongly recommend GLP-1 RAs for patients with established cardiovascular disease, regardless of diabetes status or HbA1c levels The evidence positions GLP-1 receptor agonists as fundamental cardiovascular medications rather than merely diabetes drugs with heart benefits

Thanks to the nitrate-rich vegetables, lack of processed foods, and ample extra virgin olive oil, the Mediterranean diet can lower oxidation compared to a typical diet
Alvirdizadeh et al
Du kan typisk forvente alt fra simple trehjulsformater til mere avancerede videoslots med bonusrunder, multiplikatorer og kaskadereelser
These differences matter clinically: larger average weight loss translates into bigger improvements in blood pressure, glycemic measures, sleep apnea metrics, mobility, and quality of life for many patients